BlackRock Discloses Passive Stake in Tarsus Pharmaceuticals
Ticker: TARS · Form: SC 13G · Filed: Jan 26, 2024 · CIK: 1819790
| Field | Detail |
|---|---|
| Company | Tarsus Pharmaceuticals, Inc. (TARS) |
| Form Type | SC 13G |
| Filed Date | Jan 26, 2024 |
| Risk Level | low |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: institutional-ownership, passive-investment, SC-13G
TL;DR
**BlackRock just revealed a significant, passive stake in Tarsus Pharma as of year-end 2023.**
AI Summary
BlackRock, Inc. has filed an SC 13G indicating its ownership in Tarsus Pharmaceuticals, Inc. as of December 31, 2023. This filing, made under Rule 13d-1(b), signifies that BlackRock holds a significant, but passive, stake in Tarsus Pharmaceuticals. This matters to investors because BlackRock's substantial position can signal confidence in the company's long-term prospects, potentially influencing other institutional investors and providing a degree of stability to the stock.
Why It Matters
This filing shows a major institutional investor, BlackRock, has a notable stake in Tarsus Pharmaceuticals, which can be seen as a vote of confidence.
Risk Assessment
Risk Level: low — This filing indicates a passive investment by a large institution, which generally reduces volatility and signals stability rather than immediate risk.
Analyst Insight
Investors should note BlackRock's passive stake as a potential indicator of long-term institutional interest in Tarsus Pharmaceuticals, but this filing alone doesn't suggest immediate price action.
Key Players & Entities
- BlackRock, Inc. (company) — the reporting person and institutional investor
- Tarsus Pharmaceuticals, Inc. (company) — the subject company in which BlackRock holds shares
- December 31, 2023 (date) — the date of the event requiring the filing
- Rule 13d-1(b) (person) — the specific SEC rule under which the filing was made
FAQ
What type of filing is this document?
This document is an SC 13G filing, specifically under Rule 13d-1(b) of the Securities Exchange Act of 1934, as indicated by the 'FORM TYPE: SC 13G' and the checked box '[X] Rule 13d-1(b)'.
Who is the 'subject company' in this filing?
The 'subject company' is Tarsus Pharmaceuticals, Inc., as stated under 'SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Tarsus Pharmaceuticals, Inc.'.
Who is the 'reporting person' making this filing?
The 'reporting person' is BlackRock, Inc., as identified under 'FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BlackRock Inc.' and 'Names of reporting persons. BlackRock, Inc.'.
What is the CUSIP number for the securities mentioned in this filing?
The CUSIP number for the Common Stock of Tarsus Pharmaceuticals, Inc. is 87650L103, as listed under 'CUSIP No. 87650L103'.
What was the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' was December 31, 2023, as explicitly stated in the filing.
Filing Details
This Form SC 13G (Form SC 13G) was filed with the SEC on January 26, 2024 by Rule 13d-1(b) regarding Tarsus Pharmaceuticals, Inc. (TARS).